Abstract
The purpose of the study was to formulate a conventional (immediate release) tablet using a combination of Dapsone and Fexofenadine HCl. Dapsone is a sulfone with anti-inflammatory, immunosuppressive, antibiotic, and antibacterial properties. Fexofenadine HCl is a non-sedating antihistamine approved for the treatment of allergies, whereas Dapsone is used to prevent bacteria from growing and causing red, itching welts. Fexofenadine HCl is an antihistamine that is used to treat allergic symptoms by blocking a natural substance called histamine. Direct compression methods were used to formulate the tablets, which contained super disintegrating polymers such as Ac-di-sol (Croscarmellose sodium). Four tablet formulations were compounded using the direct compression method, with polymer varying ratios. According to the evaluation results, formulations met the specifications when compared to official pharmacopoeias and standards. Different parameters, such as hardness, friability, weight variation, and dissolution studies, were used to evaluate tablets. This formulation of tablet combination of Dapsone and Fexofenadine HCl releases the drug within 60 minutes. Thus, the trial was a success in terms of achieving our goal of developing a tablet with few excipients and a simple manufacturing method.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
